This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Tjaard U. Hoogenraad, MD
University Department of Neurology Heidelberglaan 100 3584 CX Utrecht the Netherlands

Arch Neurol. 1994;51(10):972-973.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In their letter to the editor, Lang et al¹ reported on the fatal outcome of a 30-year-old male patient with Wilson's disease. He was known to have had the disease since the age of 13 years and had been administered penicillamine therapy. However, he had discontinued the treatment, because he had felt perfectly sound. After about 3 years without medication, he started treatment with oral zinc sulfate at a dose of 200 mg thrice daily. During the first 4 weeks, he continued to feel quite well, but thereafter he began to develop symptoms indicative of progressive hepatic failure, while he also developed neurologic symptoms. After treatment with penicillamine was resumed, his hepatic and neurologic conditions deteriorated. While the patient was receiving a highdose penicillamine, the neurologic deterioration became severe and he died after esophageal hemorrhaging and failure of central cerebral regulation.

The authors made reference to the letter to . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?